EUVIMEDEUVIMED entdecken
Crossref

Immune checkpoint inhibitors for the treatment of glioblastoma: Where we are

Bryan Lu, Senxi Du, Xiao-Tang Kong

Journal of Solid Tumors · 2020

DOI: 10.5430/jst.v10n1p7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Solid Tumors, 2020. Verfasst von Bryan Lu und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite a history of frequent challenges and roadblocks, there has been recent excitement in the treatment of human cancer, specifically regarding the remarkable efficacy of various immune checkpoint inhibitors including programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockers in treating metastatic melanoma, non-small cell lung cancer, and other malignant growths. However, treatment of glioblastoma multiforme (GBM) with immune checkpoint inhibitors so far has not been shown to be as successful in several randomized clinical trials as in other cancer with the exception of one pilot study that found promising results by neoadjuvant administration of Pembrolizimab for the treatment of recurrent GBM. Our article will review the current status of immune checkpoint inhibitors for the treatment of GBM.

Zitieren

APA

Lu, B., Du, S., & Kong, X. (2020). Immune checkpoint inhibitors for the treatment of glioblastoma: Where we are. Journal of Solid Tumors. https://doi.org/10.5430/jst.v10n1p7

Vancouver

Lu B, Du S, Kong X. Immune checkpoint inhibitors for the treatment of glioblastoma: Where we are. Journal of Solid Tumors. 2020. doi:10.5430/jst.v10n1p7

BibTeX
@article{Lu2020,
  author = {Lu, Bryan and Du, Senxi and Kong, Xiao-Tang},
  title = {Immune checkpoint inhibitors for the treatment of glioblastoma: Where we are},
  journal = {Journal of Solid Tumors},
  year = {2020},
  doi = {10.5430/jst.v10n1p7}
}
Kostenlos starten →